CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

Korea University Study Reveals How a Blood Biomarker Tracks Response to Lecanemab in Early Alzheimer's Disease

Data ReadoutLecanemabPositive
AI Analysis

Summary

Korea University published a study investigating plasma p-tau217 as a potential biomarker for tracking treatment response to lecanemab in early Alzheimer's disease patients.

Outcome Details

Study investigates plasma p-tau217 as a potential early marker of treatment response to lecanemab in early Alzheimer's disease

Importance:4/10
Sentiment:
0.30
Alzheimer's DiseaseBiomarkerTreatment Responsep-tau217Korea UniversityResearch
Related Companies
$MRKR

Read the original article

Published by PR Newswire Pharma on September 14, 2026 12:44 PM

Read Original